Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Blinded, Double-dummy, Placebo-controlled, 3-period Cross-over Study to Evaluate the Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control
Brief Summary: This study assessed the effect of QVA149 on patient-reported dyspnea in moderate to severe Chronic Obstructive Pulmonary Disease (COPD) patients.


Options:
A: Arm Label: QVA149 + placebo to tiotropium; Type: EXPERIMENTAL; Interventions: Drug: QVA149, Drug: Placebo to tiotropium, Drug: Salbutamol/albuterol | Arm Label: Tiotropium + placebo to QVA149; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium, Drug: Placebo to QVA149, Drug: Salbutamol/albuterol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to QVA149, Drug: Placebo to tiotropium, Drug: Salbutamol/albuterol | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 + placebo to tiotropium | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium + placebo to QVA149 | Intervention Type: DRUG; Name: Placebo to QVA149; Assigned to Arm(s): Placebo, Tiotropium + placebo to QVA149 | Intervention Type: DRUG; Name: Placebo to tiotropium; Assigned to Arm(s): Placebo, QVA149 + placebo to tiotropium | Intervention Type: DRUG; Name: Salbutamol/albuterol; Assigned to Arm(s): Placebo, QVA149 + placebo to tiotropium, Tiotropium + placebo to QVA149
B: Arm Label: Fluticasone Furoate / GW642444 (vilanterol); Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg, Drug: Double-dummy placebo, Drug: Salbutamol as needed | Arm Label: Fluticasone Propionate / salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Propionate 250mcg / salmeterol 50mcg, Drug: Double-dummy placebo, Drug: Salbutamol as needed | Intervention Type: DRUG; Name: Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg; Assigned to Arm(s): Fluticasone Furoate / GW642444 (vilanterol) | Intervention Type: DRUG; Name: Fluticasone Propionate 250mcg / salmeterol 50mcg; Assigned to Arm(s): Fluticasone Propionate / salmeterol | Intervention Type: DRUG; Name: Double-dummy placebo; Assigned to Arm(s): Fluticasone Furoate / GW642444 (vilanterol), Fluticasone Propionate / salmeterol | Intervention Type: DRUG; Name: Salbutamol as needed; Assigned to Arm(s): Fluticasone Furoate / GW642444 (vilanterol), Fluticasone Propionate / salmeterol
C: Intervention Type: DRUG; Name: Test: Tiotropium 18 µg per day (one inhalation capsule) plus 12 µg formoterol twice daily (two times one inhalation capsule); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Reference: Salmeterol MDI 50 µg (2 puffs of 25 µg each) b.i.d., plus fluticasone propionate MDI 500 µg (2 puffs of 250 µg each) b.i.d.; Assigned to Arm(s): N/A
D: Arm Label: GFF MDI (PT003); Type: EXPERIMENTAL; Interventions: Drug: GFF MDI (PT 003) | Arm Label: GP MDI (PT001); Type: EXPERIMENTAL; Interventions: Drug: GP MDI (PT001) | Arm Label: FF MDI (PT005); Type: EXPERIMENTAL; Interventions: Drug: FF MDI (PT005) | Arm Label: Open-label tiotropium bromide inhalation powder; Type: ACTIVE_COMPARATOR; Interventions: Drug: Open-label tiotropium bromide inhalation (Spiriva® Handihaler®) | Intervention Type: DRUG; Name: GFF MDI (PT 003); Assigned to Arm(s): GFF MDI (PT003) | Intervention Type: DRUG; Name: GP MDI (PT001); Assigned to Arm(s): GP MDI (PT001) | Intervention Type: DRUG; Name: FF MDI (PT005); Assigned to Arm(s): FF MDI (PT005) | Intervention Type: DRUG; Name: Open-label tiotropium bromide inhalation (Spiriva® Handihaler®); Assigned to Arm(s): Open-label tiotropium bromide inhalation powder

Answer: A